NASDAQ NMS - GLOBAL MARKET · INTS
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Intensity Therapeutics Inc

Intensity Therapeutics Inc

Biotechnology
$4.86
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
INTS
Intensity Therapeutics Inc
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

65/ 100
Veridion Score
BUY BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is INTS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading INTS catalysts
About Intensity Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2023
Employees
7
Country
US

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.86
Last session
Day high
$4.86
Last session
Day low
$4.86
Last session
Previous close
$4.86
52W high
$33.00
-85.27% from high
52W low
$3.62
4% of range
Market cap
$15.9M
EPS
$-2.2600
Beta
0.28
Shares out
3.3M
Avg volume
28.2K
VWAP
$4.86
Last session
Price history computed in-house
1W
+17.11%
1M
+9.21%
3M
+3.85%
1Y
-36.07%
YTD
-52.61%
SMA 50 $4.31 · above
SMA 200 $6.97 · below
52W position 4%

INTS overview

Veridion Score
65
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around INTS.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading INTS Form 4 filings
Public disclosures

Congress activity in INTS

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for INTS in the cached public ledger.

Federal contracts

INTS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for INTS in this window.
Lobbying spend

INTS lobbying filings, year to date.

Registered lobbying filings matched to Intensity Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for INTS in this window.
Loading news for INTS
Analyst ratings
Sovereign unlock shows live analyst consensus for INTS.
Options
Sovereign unlock shows live options positioning for INTS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.